Literature DB >> 26807205

Chronic hepatitis C: This and the new era of treatment.

Gaetano Bertino1, Annalisa Ardiri1, Maria Proiti1, Giuseppe Rigano1, Evelise Frazzetto1, Shirin Demma1, Maria Irene Ruggeri1, Laura Scuderi1, Giulia Malaguarnera1, Nicoletta Bertino1, Venerando Rapisarda1, Isidoro Di Carlo1, Adriana Toro1, Federico Salomone1, Mariano Malaguarnera1, Emanuele Bertino1, Michele Malaguarnera1.   

Abstract

Over the last years it has started a real revolution in the treatment of chronic hepatitis C. This occurred for the availability of direct-acting antiviral agents that allow to reach sustained virologic response in approximately 90% of cases. In the near future further progress will be achieved with the use of pan-genotypic drugs with high efficacy but without side effects.

Entities:  

Keywords:  Boceprevir; Daclatasvir; Dasabuvir; Direct-acting antiviral agents; Faldaprevir; Hepatitis C; Ledipasvir; Nucleoside inhibitors; Ombitasvir; Ritonavir; Simeprevir; Sofosbuvir; Telaprevir

Year:  2016        PMID： 26807205      PMCID： PMC4716531          DOI： 10.4254/wjh.v8.i2.92

Source DB:  PubMed          Journal:  World J Hepatol


  132 in total

1.  ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.

Authors:  Peter Ferenci; David Bernstein; Jacob Lalezari; Daniel Cohen; Yan Luo; Curtis Cooper; Edward Tam; Rui T Marinho; Naoky Tsai; Anders Nyberg; Terry D Box; Ziad Younes; Pedram Enayati; Sinikka Green; Yaacov Baruch; Bal Raj Bhandari; Florin Alexandru Caruntu; Thomas Sepe; Vladimir Chulanov; Ewa Janczewska; Giuliano Rizzardini; Judit Gervain; Ramon Planas; Christophe Moreno; Tarek Hassanein; Wangang Xie; Martin King; Thomas Podsadecki; K Rajender Reddy
Journal:  N Engl J Med       Date:  2014-05-04       Impact factor: 91.245

Review 2.  Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.

Authors:  Jean-Michel Pawlotsky
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

Review 3.  Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma.

Authors:  G Bertino; S Neri; C M Bruno; A M Ardiri; G S Calvagno; M Malaguarnera; A Toro; M Malaguarnera; S Clementi; N Bertino; I Di Carlo
Journal:  Minerva Med       Date:  2011-10       Impact factor: 4.806

4.  Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010.

Authors:  Reena Mahajan; Jian Xing; Stephen J Liu; Kathleen N Ly; Anne C Moorman; Loralee Rupp; Fujie Xu; Scott D Holmberg
Journal:  Clin Infect Dis       Date:  2014-02-12       Impact factor: 9.079

5.  Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.

Authors:  Sarah Maylin; Michelle Martinot-Peignoux; Rami Moucari; Nathalie Boyer; Marie-Pierre Ripault; Dominique Cazals-Hatem; Nathalie Giuily; Corinne Castelnau; Ana Carolina Cardoso; Tarik Asselah; Cyrille Féray; Marie Hélène Nicolas-Chanoine; Pierre Bedossa; Patrick Marcellin
Journal:  Gastroenterology       Date:  2008-05-21       Impact factor: 22.682

6.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

7.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

Review 8.  Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir.

Authors:  Brian J Kirby; William T Symonds; Brian P Kearney; Anita A Mathias
Journal:  Clin Pharmacokinet       Date:  2015-07       Impact factor: 6.447

9.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

10.  Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies.

Authors:  Namiki Izumi; Norio Hayashi; Hiromitsu Kumada; Takeshi Okanoue; Hirohito Tsubouchi; Hiroshi Yatsuhashi; Mai Kato; Rito Ki; Yuji Komada; Chiharu Seto; Shoichiro Goto
Journal:  J Gastroenterol       Date:  2014-03-14       Impact factor: 6.772
View more
  25 in total

1.  No longer 'written off' - times have changed for the BBV-infected dental professional.

Authors:  J Bagg; K Roy; L Hopps; I Black; D Croser; C O'Halloran; F Ncube
Journal:  Br Dent J       Date:  2017-01-13       Impact factor: 1.626

Review 2.  Hepatocellular carcinoma and the risk of occupational exposure.

Authors:  Venerando Rapisarda; Carla Loreto; Michele Malaguarnera; Annalisa Ardiri; Maria Proiti; Giuseppe Rigano; Evelise Frazzetto; Maria Irene Ruggeri; Giulia Malaguarnera; Nicoletta Bertino; Mariano Malaguarnera; Vito Emanuele Catania; Isidoro Di Carlo; Adriana Toro; Emanuele Bertino; Dario Mangano; Gaetano Bertino
Journal:  World J Hepatol       Date:  2016-05-08

Review 3.  Hepatitis C virus: Promising discoveries and new treatments.

Authors:  Juliana Cristina Santiago Bastos; Marina Aiello Padilla; Leonardo Cardia Caserta; Noelle Miotto; Aline Gonzalez Vigani; Clarice Weis Arns
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

4.  HCV treatment barriers among HIV/HCV co-infected patients in the US: a qualitative study to understand low uptake among marginalized populations in the DAA era.

Authors:  Tessa M Nápoles; Abigail W Batchelder; Ada Lin; Lissa Moran; Mallory O Johnson; Martha Shumway; Anne F Luetkemeyer; Marion G Peters; Kellene V Eagen; Elise D Riley
Journal:  J Public Health (Oxf)       Date:  2019-12-20       Impact factor: 2.341

5.  Predictors of outcomes following liver transplant in hepatopulmonary syndrome: An OPTN database analysis.

Authors:  Arun Jose; Shimul A Shah; Nadeem Anwar; Courtney R Jones; Francis X McCormack; Kenneth E Sherman; Jean M Elwing
Journal:  Respir Med       Date:  2021-11-11       Impact factor: 3.415

Review 6.  Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection.

Authors:  Iman Ibrahim Salama; Hala M Raslan; Ghada A Abdel-Latif; Somaia I Salama; Samia M Sami; Fatma A Shaaban; Aida M Abdelmohsen; Walaa A Fouad
Journal:  World J Hepatol       Date:  2022-06-27

7.  Real-world efficacy and safety of Ledipasvir + Sofosbuvir and Ombitasvir/Paritaprevir/Ritonavir ± Dasabuvir combination therapies for chronic hepatitis C: A Turkish experience.

Authors:  Bülent Değertekin; Mehmet Demir; Ulus S Akarca; Haluk Tarık Kani; Enver Üçbilek; Emre Yıldırım; Fatih Güzelbulut; Ayhan Balkan; Sezgin Vatansever; Nilay Danış; Melek Demircan; Aliye Soylu; Serkan Yaras; Aysun Kartal; Ayşe Kefeli; Feyza Gündüz; Kendal Yalçın; Elife Erarslan; Murat Aladağ; Murat Harputluoğlu; Ayşegül Özakyol; Tuncer Temel; Mesut Akarsu; Hale Sümer; Mete Akın; Bülent Albayrak; İlker Sen; Hüseyin Alkım; Ahmet Uyanıkoğlu; Kader Irak; Sinem Öztaşkın; Çağrı Burak Uğurlu; Şevkican Güneş; Selim Gürel; Kenan Nuriyev; İsmail İnci; Sabite Kaçar; Dinç Dinçer; Levent Doğanay; Hüseyin Savaş Göktürk; Ali Mert; Arif Mansur Coşar; Hakan Dursun; Roni Atalay; Sabiye Akbulut; Yasemin Balkan; Hayrettin Koklu; Halis Şimşek; Osman Özdoğan; Mehmet Çoban
Journal:  Turk J Gastroenterol       Date:  2020-12       Impact factor: 1.852

Review 8.  Depression, fatigue and neurocognitive deficits in chronic hepatitis C.

Authors:  Sern Wei Yeoh; Alex C N Holmes; Michael M Saling; Ian P Everall; Amanda J Nicoll
Journal:  Hepatol Int       Date:  2018-06-21       Impact factor: 6.047

9.  Viekira Pak Induced Fatal Lactic Acidosis: A Case Report of an Unusual Side Effect.

Authors:  Molham Abdulsamad; Ariyo Ihimoyan
Journal:  Case Reports Hepatol       Date:  2016-12-01

10.  Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability.

Authors:  Giulia Malaguarnera; Gaetano Bertino; Giuseppe Chisari; Massimo Motta; Michele Vecchio; Marco Vacante; Filippo Caraci; Carmela Greco; Filippo Drago; Giuseppe Nunnari; Michele Malaguarnera
Journal:  BMC Psychiatry       Date:  2016-11-15       Impact factor: 3.630
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.